EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Study of the Role of the Tumor Microenvironment in Ovarian Cancer ( MICO ): A Prospective Monocentric Trial

Martina Arcieri iD, Eleonora Capezzali iD, Stefano Restaino, Sara Pregnolato, Laura Mariuzzi, Alessandro Mangogna iD, Maria Orsaria, Angelica Tulisso, Silvia Tonon, Maria De Martino, Miriam Isola, Lorenza Driul und 4 weitere

Cancer Reports · 2025

DOI: 10.1002/cnr2.70242 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Reports, 2025. Verfasst von Martina Arcieri und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Obstetrics and Gynecology, "Santa Maria Della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, It…. Hauptthemen laut MEDLINE: Cystadenocarcinoma, Serous, Ovarian Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero dell'Università e della Ricerca, RicLib Departmental Strategic Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian cancer (OC) is one of the most aggressive tumors requiring new therapeutic approaches. Immunotherapy represents an opportunity, but to date, OC patients do not appear to benefit from current protocols. A better understanding of the composition of the tumor microenvironment (TME), especially in its immune components, could unveil mechanisms of immune suppression in a useful way to predict response to therapies and develop new therapeutic approaches.

Method

The MICO (tumor MICroenvironment of Ovarian cancer) study is a single‐center observational study. Starting from peritoneal biopsy of high‐grade serous ovarian carcinoma (HGSOC), the purpose of the MICO study is to generate tumor patient‐derived organoid (PDOs) cultures and evaluate the concordance between in vitro platinum‐based chemotherapy sensitivity and in vivo sensitivity. Simultaneously, we will characterize through multiparameter cytofluorimetric analysis the composition of the OC TME, focusing on B lymphocytes and mast cells whose roles in ovarian cancer remain controversial and underinvestigated. Furthermore, patients experiencing recurrence will be longitudinally followed to monitor changes in the TME composition and the responsiveness of PDOs to in vitro stimulation with drugs.

Discussion

The association between the composition of the TME, the reactivity of the PDOs, and patients' disease progression will be analyzed to identify whether specific subpopulations of tumor‐infiltrating immune cells could be predictive factors of the disease outcomes. The comparison of molecular profiles, in vitro response to drugs, and clinical‐pathological data will allow the definition of a pattern capable of predicting the response of the primary tumor for the identification of those patients who may benefit from specific treatment. Strengths and Limitations The results of our study could help to better understand the OC behavior, may have implications for the development of effective immunotherapy and targeted pharmacological therapies for epithelial OC in a personalized medicine perspective. This will be a monocentric trial with an involvement of only 43 patients, so further studies will need to confirm our results. Trial Registration The clinical trial has been registered at Clinical‐Trials.gov with the identifier NCT06272240 on 02/14/2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystadenocarcinoma, SerousOvarian NeoplasmsTumor MicroenvironmentFemaleHumansB-LymphocytesMast CellsObservational Studies as TopicOrganoidsProspective Studies

Stichwörter der Autor:innen

organoidsovarian cancertumor microenvironment

Autor:innen und Institutionen

  • Clinic of Obstetrics and Gynecology, "Santa Maria Della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
  • Department of Medicine (DMED), University of Udine, Udine, Italy.
  • Department of Obstetrics and Gynecology, University of Sassari, Sassari, Italy.
  • Institute of Pathology, Academic Hospital, Udine, Italy.
  • Gynecologic Oncology Unit, Fondazione "Policlinico Universitario A. Gemelli IRCCS," Catholic University of the Sacred Heart, Rome, Italy.
  • Institute of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.

ORCID-Profile: Martina Arcieri, Eleonora Capezzali, Alessandro Mangogna, Giuseppe Vizzielli

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Ministero dell'Università e della Ricerca
  • RicLib Departmental Strategic Plan
  • Loto OdV Onlus
  • Fondazione AIRC per la ricerca sul cancro ETS

Zitieren

APA

Arcieri, M., Capezzali, E., Restaino, S., Pregnolato, S., Mariuzzi, L., Mangogna, A., Orsaria, M., Tulisso, A., Tonon, S., De Martino, M., Isola, M., Driul, L., Pucillo, C., Scambia, G., Frossi, B., & Vizzielli, G. (2025). Study of the Role of the Tumor Microenvironment in Ovarian Cancer ( MICO ): A Prospective Monocentric Trial. Cancer Reports. https://doi.org/10.1002/cnr2.70242

Vancouver

Arcieri M, Capezzali E, Restaino S, Pregnolato S, Mariuzzi L, Mangogna A, et al. Study of the Role of the Tumor Microenvironment in Ovarian Cancer ( MICO ): A Prospective Monocentric Trial. Cancer Reports. 2025. doi:10.1002/cnr2.70242

BibTeX
@article{Arcieri2025,
  author = {Arcieri, Martina and Capezzali, Eleonora and Restaino, Stefano and Pregnolato, Sara and Mariuzzi, Laura and Mangogna, Alessandro and Orsaria, Maria and Tulisso, Angelica and Tonon, Silvia and De Martino, Maria and Isola, Miriam and Driul, Lorenza and Pucillo, Carlo and Scambia, Giovanni and Frossi, Barbara and Vizzielli, Giuseppe},
  title = {Study of the Role of the Tumor Microenvironment in Ovarian Cancer ( MICO ): A Prospective Monocentric Trial},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70242}
}
Kostenlos starten →